Apixaban is a direct FXa inhibitor, approved by FDA in 2012 for stroke prevention in NV-AF, for VTE and PE treatment, and for VTE prevention after knee or hip replacement surgery (Frost et al., 2013). Here, F10 is linked to Stroke.